spacer
home > ebr > summer 2007 > small world
PUBLICATIONS
European Biopharmaceutical Review

Small World

Stephanie Finnegan and Karl Pinto of Goodwin Biotechnology, Inc, discuss the globalisation of outsourced bioprocessing

As is now apparent, the pharmaceutical and biotherapeutics ‘industries’ are not discrete at all, but simply one industry making drugs in different ways: chemical drugs in the mature pharma sector, and protein drugs in its sister sector, biotherapeutics. To any business strategist, recognising the similarities of these two industry sectors makes predicting the paradigms that will emerge in the stillnascent biopharm sector much less complex than if it were a standalone industry. However, even subtle differences can make predictions misleading: the devil is always hiding in the details.

For example, in defining its business, the pharmaceutical industry today has properly (in most cases) acknowledged that its core competencies lie in its vast distribution network and infrastructure. As a result, pharmaceutical manufacturing can be a commodity driven, cost-centred business that is ripe for outsourcing some of those non-core competencies, such as novel drug discovery and manufacturing, especially of products nearing generic status. Manufacturers who can fully utilise their plants will perform brilliantly (both for their customers and for owners). In pharma parlance, these are collectively known as the speciality chemical, bulk API, contract, or toll manufacturing niche. But, arguably, this developmental paradigm has evolved slowly and over a long period of time in the pharmaceutical sector. Biologics are different.

Biologics are much more costly to manufacture: we still speak of costs in terms of thousands or even tens of thousands of dollars per gram! Most of them are still in the clinic. Market sizes are largely uncertain and ultimate market shares illdefined. In early stages, production yields are unpredictable and, surprisingly, even somewhat unquantifiable, due to early stage assay variability. Product approval rates are low.

Construction of manufacturing facilities is hugely capital intensive and time consuming. Add uncertain approval and inestimable market share to years of construction required to design, build and validate a plant and the result is a recipe for disaster, and a costly one at that. Maintaining a compliant facility requires tremendous fixed costs (principally skilled employees, utilities and cost of capital), regardless of plant utilisation. As a result, cost of goods is very high, as are R&D and clinical development costs.

The end result is protein drugs that are very effective, tend to have fewer side effects than chemicals, and more often attack disease at the cellular or intracellular level – aiming for a cure, not just mitigation of symptoms. The biggest threat to the success of biotherapeutics is their cost of manufacture, which nearly destroys the advantages of their broad market viability and early promise of disease solutions to the global community.

BIOTHERAPEUTICS DEVELOPMENT: OUTSOURCE EARLY AND OFTEN

The pharmaceutical sector moved slowly towards outsourcing, as drugs became generic and the sector began to focus upon its core competencies of sales, marketing and formidable logistics. The difference in the sectors, therefore, is that biotechnology drugs hold forth with even more compelling reasons to outsource – even in early clinical development.

As stated previously, reasons to outsource include the high cost of goods, difficulty of manufacture, uncertainty of approvals, inestimable demand post approval, the cyclical unavailability of capital, and the high cost of capital even when it is available. Finally, the mix is further complicated by regulatory challenges. Until the promise of harmonisation is fulfilled, global regulatory one-up-manship will continue to cause corporate regulatory whiplash around the world.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephanie Finnegan founded Goodwin Biotechnology, a contract manufacturer of bio-diagnostics and biotherapeutics, in Plantation, Florida, in 1992. Prior to forming Goodwin, she was an Ernst & Young CPA and a consultant in the corporate finance division of Redding Consultants. Stephanie has led Goodwin’s growth throughout this decade. In 2004, she negotiated the sale of Goodwin to Wallace Pharmaceuticals Pvt Ltd, based in Goa, India.

Karl Pinto is the Chairman of Goodwin and a Director of Wallace Pharmaceuticals. He was educated as an Electrical Engineer in India, and has resided in the US for more than a decade. Karl is also Managing Director of the Penser Group, which advised Wallace on the acquisition of Goodwin in 2004. Karl was responsible for assisting Wallace in developing its biotechnology strategy and executes Wallace and Goodwin’s global contract manufacturing strategy.

spacer
Stephanie Finnegan
spacer
spacer
spacer
Karl Pinto
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

‘FDA should withdraw ANDAs’, and ‘new technologies could bring massive improvements in efficiency’ if implemented correctly

Amsterdam, 21st October 2019: CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th-7th November 2019) – has released the first part of its eponymous 2019 Annual Report. Experts Bikash Chatterjee, President and Chief Science Officer at Pharmtech Associates and Girish Malhotra, President of EPCOT International discuss how manufacturing could be revolutionised by new technologies, but warn, that regulators must change to prevent hindering future innovation.
More info >>

White Papers

ECCRT

ECCRT

The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement